These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 30060063

  • 21. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
    Arbel Y, Klempfner R, Erez A, Goldenberg I, Benzekry S, Shlomo N, Fisman EZ, Tenenbaum A, BIP Study Group.
    Cardiovasc Diabetol; 2016 Jan 22; 15():11. PubMed ID: 26794137
    [Abstract] [Full Text] [Related]

  • 22. Triglycerides: A reappraisal.
    Wiesner P, Watson KE.
    Trends Cardiovasc Med; 2017 Aug 22; 27(6):428-432. PubMed ID: 28438398
    [Abstract] [Full Text] [Related]

  • 23. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.
    Patel AA, Budoff MJ.
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr 22; 23(2):145-9. PubMed ID: 26825470
    [Abstract] [Full Text] [Related]

  • 24. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.
    Tenenbaum A, Klempfner R, Fisman EZ.
    Cardiovasc Diabetol; 2014 Dec 04; 13():159. PubMed ID: 25471221
    [Abstract] [Full Text] [Related]

  • 25. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
    Schwartz LM, Woloshin S, Lu Z, Ross KM, Tessema FA, Peter D, Kesselheim AS.
    Circ Cardiovasc Qual Outcomes; 2019 Nov 04; 12(11):e006073. PubMed ID: 31707825
    [Abstract] [Full Text] [Related]

  • 26. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, Perk J, Hajage D, Henriksson KM, Borghi C.
    BMC Cardiovasc Disord; 2017 Jun 17; 17(1):160. PubMed ID: 28623902
    [Abstract] [Full Text] [Related]

  • 27. [Update of lipid lowering therapy].
    Riesen WF, Mordasini RC.
    Praxis (Bern 1994); 2008 Nov 05; 97(22):1179-84. PubMed ID: 18979436
    [Abstract] [Full Text] [Related]

  • 28. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L.
    Cardiovasc Res; 2021 Mar 21; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract] [Full Text] [Related]

  • 29. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I.
    Atheroscler Suppl; 2017 Nov 21; 30():19-27. PubMed ID: 29096837
    [Abstract] [Full Text] [Related]

  • 30. [Residual risk: The roles of triglycerides and high density lipoproteins].
    Grammer T, Kleber M, Silbernagel G, Scharnagl H, März W.
    Dtsch Med Wochenschr; 2016 Jun 21; 141(12):870-7. PubMed ID: 27305303
    [Abstract] [Full Text] [Related]

  • 31. Medical nutrition therapy is the essential cornerstone for effective treatment of "refractory" severe hypertriglyceridemia regardless of pharmaceutical treatment: Evidence from a Lipid Management Program.
    Rhodes KS, Weintraub M, Marchlewicz EH, Rubenfire M, Brook RD.
    J Clin Lipidol; 2015 Jun 21; 9(4):559-67. PubMed ID: 26228674
    [Abstract] [Full Text] [Related]

  • 32. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C, Masuda D, Koseki M, Yamashita S.
    Cardiovasc Diabetol; 2020 Nov 27; 19(1):201. PubMed ID: 33246467
    [Abstract] [Full Text] [Related]

  • 33. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story.
    Rhainds D, Brodeur MR, Tardif JC.
    Expert Opin Investig Drugs; 2019 Dec 27; 28(12):1059-1079. PubMed ID: 31752565
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Investigation and management of hypertriglyceridaemia.
    Ferns G, Keti V, Griffin B.
    J Clin Pathol; 2008 Nov 27; 61(11):1174-83. PubMed ID: 18955574
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Triglycerides and cardiovascular disease.
    Nordestgaard BG, Varbo A.
    Lancet; 2014 Aug 16; 384(9943):626-635. PubMed ID: 25131982
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Hypertriglyceridemia: A strategic approach.
    Raza Z, Mulki AK, Garufi LC, Greenberg GM.
    J Fam Pract; 2020 May 16; 69(4):180-187. PubMed ID: 32437481
    [Abstract] [Full Text] [Related]

  • 40. Lipids and Cardiovascular Disease: Putting It All Together.
    Pownall HJ, Gotto AM.
    Methodist Debakey Cardiovasc J; 2019 May 16; 15(1):5-8. PubMed ID: 31049143
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.